Compagnie Lombard Odier SCmA Purchases Shares of 210,896 Amgen Inc. (NASDAQ:AMGN)

Compagnie Lombard Odier SCmA acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 1st quarter, HoldingsChannel reports. The firm acquired 210,896 shares of the medical research company’s stock, valued at approximately $65,705,000.

A number of other institutional investors also recently modified their holdings of the company. Centricity Wealth Management LLC acquired a new stake in Amgen during the 4th quarter valued at $25,000. Pinney & Scofield Inc. bought a new stake in shares of Amgen during the fourth quarter worth $26,000. Ritter Daniher Financial Advisory LLC DE grew its holdings in shares of Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock worth $33,000 after purchasing an additional 51 shares during the last quarter. Synergy Investment Management LLC acquired a new stake in shares of Amgen in the fourth quarter valued at $34,000. Finally, Atala Financial Inc bought a new position in shares of Amgen in the fourth quarter valued at about $34,000. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Down 0.6%

AMGN opened at $291.81 on Thursday. The company has a fifty day moving average price of $280.88 and a two-hundred day moving average price of $285.46. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a market cap of $156.91 billion, a P/E ratio of 38.65, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. The firm had revenue of $8.15 billion during the quarter, compared to analysts’ expectations of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the firm posted $3.96 earnings per share. Analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the company’s stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the transaction, the senior vice president now owns 8,162 shares in the company, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.76% of the stock is currently owned by insiders.

Analysts Set New Price Targets

AMGN has been the topic of a number of research analyst reports. Bank of America increased their price objective on shares of Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a report on Wednesday, March 5th. Piper Sandler decreased their price target on shares of Amgen from $329.00 to $328.00 and set an “overweight” rating on the stock in a research note on Friday, May 16th. Morgan Stanley reissued an “equal weight” rating on shares of Amgen in a report on Friday, May 2nd. Cantor Fitzgerald assumed coverage on Amgen in a report on Tuesday, April 22nd. They set a “neutral” rating and a $305.00 price objective on the stock. Finally, Guggenheim initiated coverage on Amgen in a research report on Tuesday, May 20th. They issued a “neutral” rating and a $288.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $309.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.